Targeting Gut Microbiota in Drug Therapy: Targeting Health Through Restoration of Intestinal Viable Ecosystems (Thrive) - A New Frontier in Pharmacology

The therapeutic potential of focusing on the gut microbiota to enhance medication effectiveness and customize care is examined in this review. A promising avenue for contemporary medicine is the modulation of this microbial environment, given the mounting data that links the microbiome to human health, illness development, and treatment response. The composition of the microbiota, its function in drug metabolism, and its association with a range of physiological and pathological conditions are all critically examined in this article. Probiotics, prebiotics, postbiotics, fecal microbiota transplantation, modified microorganisms, and targeted delivery methods are among the well-known and recently developed microbiota-modulating techniques that are assessed. Although these methods have the potential to provide safer and more individualized treatments, issues such as standardization, regulatory uncertainty, and inter-individual variability still persist. It is anticipated that future developments in AI and multi-omics technology will deepen our knowledge and facilitate the application of microbiome-based precision medicine in clinical settings. Major Findings: The gut microbiota has a major impact on pharmacokinetics, pharmacodynamics, toxicity, and drug efficacy. Numerous illnesses, such as neurological, immunological, metabolic, and cancer-related disorders, have been linked to dysbiosis. Drug responsiveness can be improved and microbial equilibrium restored through precise microbiome modification. Furthermore, interactions between drugs and microbiota are reciprocal; drugs can alter the composition of microbes, and microbial enzymes can modify the effects of drugs.